CAMP4 THERAPEUTICS CORPORATION Total Liabilities
CAMP4 THERAPEUTICS CORPORATION total liabilities. Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has total liabilities worth $74.56 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of CAMP4 THERAPEUTICS CORPORATION to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CAMP4 THERAPEUTICS CORPORATION (1985–2025)
Total liabilities of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025. This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's total liabilities have evolved over time, based on quarterly financial data.
CAMP4 THERAPEUTICS CORPORATION Competitors by Total Liabilities
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viking Supply Ships AB (publ)
ST:VSSAB-B
|
Sweden | Skr1.73 Billion |
|
QORIA Ltd
AU:QOR
|
Australia | AU$175.38 Million |
|
Antipa Minerals Ltd
AU:AZY
|
Australia | AU$2.45 Million |
|
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
|
Thailand | ฿16.37 Billion |
|
Real Asset Acquisition Corp.
NASDAQ:RAAQ
|
USA | $7.00 Million |
|
Prakash Industries Limited
NSE:PRAKASH
|
India | Rs11.38 Billion |
|
Quarterhill Inc
TO:QTRH
|
Canada | CA$115.32 Million |
|
Boyaa Interactive International Limited
F:1BY
|
Germany | €562.55 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down CAMP4 THERAPEUTICS CORPORATION's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of CAMP4 THERAPEUTICS CORPORATION.
Liquidity & Leverage Metrics
CAMP4 THERAPEUTICS CORPORATION Total Liabilities Ratios Explained
CAMP4 THERAPEUTICS CORPORATION total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CAMP4 THERAPEUTICS CORPORATION's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CAMP4 THERAPEUTICS CORPORATION (1985–2025)
The table below shows the annual total liabilities of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $70.10 Million | +362.34% |
| 2024-12-31 | $15.16 Million | -91.51% |
| 2023-12-31 | $178.68 Million | -0.78% |
| 2022-12-31 | $180.08 Million | -44.09% |
| 2021-12-31 | $322.11 Million | -5.95% |
| 2020-12-31 | $342.50 Million | -4.30% |
| 2019-12-31 | $357.89 Million | -10.07% |
| 2018-12-31 | $397.97 Million | +45.20% |
| 2017-12-31 | $274.08 Million | +12.47% |
| 2016-12-31 | $243.68 Million | +25.02% |
| 2015-12-31 | $194.92 Million | +280.46% |
| 2014-12-31 | $51.23 Million | +11.09% |
| 2013-12-31 | $46.12 Million | +38.82% |
| 2012-12-31 | $33.22 Million | +25.35% |
| 2011-12-31 | $26.50 Million | -30.04% |
| 2010-12-31 | $37.88 Million | +0.34% |
| 2009-12-31 | $37.75 Million | -18.72% |
| 2008-12-31 | $46.45 Million | -33.28% |
| 2007-12-31 | $69.62 Million | -11.26% |
| 2006-12-31 | $78.45 Million | +177.83% |
| 2005-12-31 | $28.24 Million | -26.59% |
| 2004-12-31 | $38.47 Million | +19.17% |
| 2003-12-31 | $32.28 Million | +4.21% |
| 2002-12-31 | $30.97 Million | +62.10% |
| 2001-12-31 | $19.11 Million | -2.17% |
| 2000-12-31 | $19.53 Million | -28.87% |
| 1999-12-31 | $27.46 Million | +418.08% |
| 1998-12-31 | $5.30 Million | -13.11% |
| 1997-12-31 | $6.10 Million | +12.96% |
| 1996-12-31 | $5.40 Million | -44.33% |
| 1995-12-31 | $9.70 Million | +34.72% |
| 1994-12-31 | $7.20 Million | -2.70% |
| 1993-12-31 | $7.40 Million | -14.94% |
| 1992-12-31 | $8.70 Million | +61.11% |
| 1991-12-31 | $5.40 Million | +92.86% |
| 1990-12-31 | $2.80 Million | -28.21% |
| 1989-12-31 | $3.90 Million | +39.29% |
| 1988-12-31 | $2.80 Million | -48.15% |
| 1987-12-31 | $5.40 Million | 0.00% |
| 1986-12-31 | $5.40 Million | -38.64% |
| 1985-12-31 | $8.80 Million | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more